Managing Hypothyroidism in Pediatric Patients

Q4 Medicine
S. Lafranchi
{"title":"Managing Hypothyroidism in Pediatric Patients","authors":"S. Lafranchi","doi":"10.17925/USE.2018.14.2.51","DOIUrl":null,"url":null,"abstract":"Received: July 19, 2018 Published Online: September 12, 2018 Citation: US Endocrinology, 2018;14(2):51–3. Corresponding Author: Stephen H LaFranchi, Department of Pediatrics [CDRCP], Oregon Health & Science University, 707 SW Gaines St, Portland, Oregon, US. E: lafrancs@ohsu.edu T his interview explores current controversies in the management of hypothyroidism in children. Newborn screening programs have allowed early detection and treatment of babies with congenital hypothyroidism, but some programs do not detect cases with delayed thyroidstimulating hormone (TSH) elevation and most do not detect congenital central hypothyroidism. Lack of harmonization of TSH cut-offs means that some programs do not detect milder cases of congenital hypothyroidism. Detection of such mild cases is controversial as most patients have transient hypothyroidism and the benefit of treatment is not proven. The most common disorder of thyroid function in children is subclinical hypothyroidism—many of these cases represent TSH assay artifacts or are associated with obesity, but some will progress to overt hypothyroidism. Some patients/parents are not happy with levothyroxine treatment alone, which raises the consideration of combination thyroxine and triiodothyronine (T4 and T3) treatment. Further research, including randomized clinical trials, is required to resolve these issues.","PeriodicalId":23490,"journal":{"name":"US endocrinology","volume":"14 1","pages":"51"},"PeriodicalIF":0.0000,"publicationDate":"2018-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"US endocrinology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.17925/USE.2018.14.2.51","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

Abstract

Received: July 19, 2018 Published Online: September 12, 2018 Citation: US Endocrinology, 2018;14(2):51–3. Corresponding Author: Stephen H LaFranchi, Department of Pediatrics [CDRCP], Oregon Health & Science University, 707 SW Gaines St, Portland, Oregon, US. E: lafrancs@ohsu.edu T his interview explores current controversies in the management of hypothyroidism in children. Newborn screening programs have allowed early detection and treatment of babies with congenital hypothyroidism, but some programs do not detect cases with delayed thyroidstimulating hormone (TSH) elevation and most do not detect congenital central hypothyroidism. Lack of harmonization of TSH cut-offs means that some programs do not detect milder cases of congenital hypothyroidism. Detection of such mild cases is controversial as most patients have transient hypothyroidism and the benefit of treatment is not proven. The most common disorder of thyroid function in children is subclinical hypothyroidism—many of these cases represent TSH assay artifacts or are associated with obesity, but some will progress to overt hypothyroidism. Some patients/parents are not happy with levothyroxine treatment alone, which raises the consideration of combination thyroxine and triiodothyronine (T4 and T3) treatment. Further research, including randomized clinical trials, is required to resolve these issues.
小儿甲状腺功能减退症的处理
收稿日期:2018年7月19日在线发布日期:2018年9月12日引文:美国内分泌杂志,2018;14(2):51-3。通讯作者:Stephen H LaFranchi,俄勒冈健康与科学大学儿科[CDRCP], 707 SW Gaines St, Portland, Oregon, US。E: lafrancs@ohsu.edu本次访谈探讨了目前在儿童甲状腺功能减退症治疗方面的争议。新生儿筛查项目可以早期发现和治疗先天性甲状腺功能减退症婴儿,但一些项目不能检测出促甲状腺激素(TSH)延迟升高的病例,大多数不能检测出先天性中枢性甲状腺功能减退症。缺乏协调的TSH切断意味着一些程序不检测轻微的先天性甲状腺功能减退症。这种轻微病例的检测存在争议,因为大多数患者都有短暂性甲状腺功能减退,治疗的益处尚未得到证实。儿童中最常见的甲状腺功能紊乱是亚临床甲状腺功能减退症,其中许多病例表现为TSH检测伪影或与肥胖有关,但有些会发展为明显的甲状腺功能减退症。部分患者/家长对单用左甲状腺素治疗不满意,这就提出了甲状腺素联合三碘甲状腺原氨酸(T4、T3)治疗的考虑。解决这些问题需要进一步的研究,包括随机临床试验。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
US endocrinology
US endocrinology Medicine-Endocrinology, Diabetes and Metabolism
CiteScore
1.90
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信